Welcome to our dedicated page for Biodexa Pharmaceuticals plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biodexa Pharmaceuticals plc (NASDAQ: BDRX) SEC filings page on Stock Titan provides direct access to the company’s US regulatory disclosures as a foreign private issuer. Biodexa reports to the Securities and Exchange Commission primarily through Form 20-F for its annual report and Form 6-K for current reports on material developments. These filings document clinical, regulatory and financing milestones for its lead programs eRapa, tolimidone and MTX110.
Recent Form 6-K filings describe key events such as the approval of a Clinical Trial Application (CTA) by the European Medicines Agency for the pivotal Phase 3 Serenta trial of eRapa in familial adenomatous polyposis (FAP), enrollment of the first patients into that trial, and related press releases. Other 6-Ks outline corporate actions including ADR ratio changes, results of the company’s annual general meeting, and details of capital-raising transactions like equity line of credit arrangements and a best-efforts public offering of ADS Units and pre-funded units with accompanying Series L warrants.
Through these filings, investors can review information on offering structures, warrant terms, use of proceeds, grant funding supporting the eRapa FAP program, and updates on cash and cash equivalents at specified dates. The exhibits attached to 6-Ks often include full text of securities purchase agreements, placement agency agreements and warrant forms, providing additional detail on financing terms.
Stock Titan enhances access to BDRX filings with real-time updates from EDGAR and AI-powered summaries that explain the key points of lengthy documents such as current reports and registration-related materials. Users can quickly understand how new financings, clinical trial milestones or regulatory approvals described in Form 6-K may relate to Biodexa’s broader development strategy, while still having the option to read the full SEC documents for complete context.
Biodexa Pharmaceuticals PLC is registering the issuance of up to 489,000 American Depositary Shares (each ADS = 100,000 Ordinary Shares) representing 48,900,000,000 Ordinary Shares issuable upon exercise of Pre-Funded Warrants, plus up to 6,097,562 ADS representing 609,756,200,000 Ordinary Shares issuable upon exercise of Series L Warrants, and up to 152,439 ADS representing 15,243,900,000 Ordinary Shares issuable upon exercise of Placement Agent Warrants.
The prospectus describes exercise prices (Pre-Funded Warrants at $0.0001 per Depositary Share; Series L and Placement Agent Warrants at $3.28 per Depositary Share), cash‑or‑cashless exercise mechanics, beneficial ownership limits (commonly 9.99% or 4.99%) and plan of distribution terms. It also states 324,156,808,922 Ordinary Shares outstanding as of March 12, 2026 and a pro forma total of 998,056,908,922 Ordinary Shares assuming full exercise of the referenced warrants.
Biodexa Pharmaceuticals PLC registered for resale an aggregate of 943,400,000 Ordinary Shares represented by 9,434 Depositary Shares, issuable upon exercise of Series G warrants. The prospectus states the company will not receive any proceeds from resale by the selling shareholders; net proceeds will go to those selling shareholders, although the company would receive proceeds if warrants are exercised for cash. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 12, 2026.
Biodexa Pharmaceuticals PLC registers for resale 1,701,800,000 Ordinary Shares represented by 17,018 Depositary Shares, each Depositary Share representing 100,000 Ordinary Shares, for sale from time to time by identified selling shareholders.
The prospectus states the Company will receive no proceeds from resale by the selling shareholders, although the Company may receive proceeds if Series J warrants are exercised for cash; if all Series J warrants were exercised for cash in full, proceeds would be approximately $4.3 million. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 1, 2026.
Biodexa Pharmaceuticals PLC registers for resale 171,700,000 Ordinary Shares represented by 1,717 Depositary Shares, issuable upon exercise of pre-funded warrants from a December 2023 private placement. The prospectus states the Company will receive proceeds only if warrants are exercised for cash at an exercise price of $0.025 per share; otherwise all net proceeds will go to the selling shareholders. The Depositary Shares trade on NASDAQ under the symbol BDRX and each Depositary Share represents 100,000 Ordinary Shares. The prospectus discloses 324,156,808,922 Ordinary Shares outstanding as of March 12, 2026 and notes potential sales may occur in market, negotiated or brokered transactions.
Biodexa Pharmaceuticals PLC registers for resale up to 299,261,540,000 Ordinary Shares represented by 2,992,615 Depositary Shares (ADS) held or issuable to C/M Capital Master Fund, LP under an equity line Purchase Agreement.
The shares are being registered for resale by the Selling Shareholder; Biodexa is not selling shares here and will not receive proceeds from resale, although Biodexa may receive up to $35.0 million in aggregate gross proceeds if it elects to sell Depositary Shares to the Selling Shareholder under the Purchase Agreement. Each Depositary Share represents 100,000 Ordinary Shares. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 12, 2026.
Biodexa Pharmaceuticals PLC files a resale prospectus registering an aggregate of 109,800,000 Ordinary Shares, represented by 1,098 Depositary Shares, issuable upon exercise of Series D Warrants.
The prospectus states we will not receive proceeds from sales by the selling shareholders; proceeds will go to those sellers, though the company may receive proceeds if warrants are exercised for cash. Shares outstanding were 324,156,808,922 Ordinary Shares as of March 12, 2026.